📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1,000+ announcements match the current filters (relevance ≥ 5).
Anupam Rasayan Takes Majority Control (50.07%) in Bliss GVS Pharma via ₹162.7 Cr Market Buy & SPA
Anupam Rasayan has acquired controlling stake and promoter status in Bliss GVS Pharma Limited, reaching a combined 50.07% holding (5,32,36,264 shares) alongside its PAC on September 28, 2026. This follows the completion of the SPA for 47.95% (5,09,84,595 shares) and an additional on-market purchase of 22,50,000 shares (2.12%) for an aggregate cash consideration of ₹162.74 crore at ₹723.29 per share. Bliss GVS reported FY26 turnover of ₹798.98 crore (down from ₹1,000.64 crore in FY24) and net worth of ₹1,231.76 crore. The strategic acquisition extends Anupam Rasayan forward into finished dosage formulations and global pharma markets.
Confidence: HIGH
What changedAnupam Rasayan completed the acquisition under the SPA and additional market purchases, crossing 50.07% ownership and officially becoming the promoter of Bliss GVS Pharma.
Why it mattersAdds ~₹800 crore of pharma revenue (~31% of Anupam's TTM revenue of ₹2,535 crore) and forwards integrates the business from specialty chemical intermediates into finished formulations.
Total stake acquired (with PAC): 50.07%On-market consideration: INR 162,73,98,675.00Acquisition price per share: Rs. 723.2883Target FY26 turnover: Rs. 798,98,23,000Bliss FY26 revenue vs Anupam TTM revenue: ~31.5%
📅 Short termStock reaction will reflect the formal takeover of Bliss GVS and the cash deployment of ₹162.74 cr for the recent market tranche.
📈 Long termExpands Anupam's capability into finished dosage forms across 60+ countries, but integration execution is critical as Bliss GVS revenue declined from ₹1,000.6 cr in FY24 to ₹798.98 cr in FY26.
⚠ Risk flags
- Target company Bliss GVS revenue has contracted over the last two years (from ₹1,000.6 cr in FY24 to ₹798.98 cr in FY26)
- Integration risks entering downstream finished formulations
Key Highlights
Anupam Rasayan and PAC acquired 50.07% stake (5,32,36,264 shares) taking full promoter control of Bliss GVS Pharma.
SPA completed for 5,09,84,595 shares (47.95%) plus 22,50,000 shares (2.12%) acquired via on-market purchase on 28 September 2026.
Market acquisition completed for ₹162.74 crore in cash at ₹723.2883 per share.
Target company Bliss GVS Pharma reported FY26 turnover of ₹798.98 crore and net worth of ₹1,231.76 crore as on March 31, 2026.
👀 What to Watch
Track the integration timeline, consolidation of Bliss GVS financials into Anupam Rasayan's quarterly P&L, and management commentary regarding margin impacts and pharma synergies.
BLS Subsidiary to Sell JLG Lending Business for Rs 59.49 Lakh in Related Party Slump Sale
BLS International Services announced that its step-down subsidiary, Atyati Technologies Private Limited (ATPL), approved the slump sale of its Joint Liability Group (JLG) financial lending business to Tvam Technologies for Rs 59.49 lakh. The JLG unit generated Rs 100.56 crore in turnover during FY26 (26.8% of ATPL's total turnover and ~3.2% of BLS's TTM revenue of Rs 3,179 crore). Its computed net worth as of July 1, 2026, was Rs 59.49 lakh (0.9% of ATPL's net worth). The transaction is classified as a related-party deal at arm's length, as an ATPL director is a director and member in TVAM, and is slated to close within 90 days.
Confidence: HIGH
What changedATPL, a step-down subsidiary of BLS, is divesting its JLG financial lending division to TVAM Technologies on a going-concern slump sale basis.
Why it mattersThe sale sheds Rs 100.56 crore in top-line revenue (~3.2% of consolidated TTM revenue) to streamline operations and re-focus core resources, while involving a related-party entity.
Sale Consideration: Rs. 59,49,000/-FY26 Turnover of JLG Business: Rs. 100.56 CroresShare of ATPL Turnover: 26.8%Unit Net Worth (as of July 1, 2026): Rs. 59.49 lacsJLG Revenue vs BLS TTM Revenue: ~3.2%
📅 Short termMinimal financial impact given the modest consideration of Rs 59.49 lakh, though investors will note the minor revenue reduction.
📈 Long termSupports operational restructuring by shedding micro-lending operations to concentrate on higher-margin core visa, consular, and digital services.
⚠ Risk flags
- Related-party transaction (ATPL director is a director and shareholder in buyer entity TVAM)
- Execution subject to approvals/consents from lenders and regulatory authorities within 90 days
Key Highlights
Consideration for slump sale set at Rs 59,49,000, subject to post-closing adjustments
JLG Business unit contributed Rs 100.56 Crores in turnover in FY25-26, representing 26.8% of ATPL's revenue
Unit net worth stood at Rs 59.49 lacs as of July 1, 2026, representing 0.9% of ATPL's total net worth
Transaction is a related party transaction entered at arm's length and expected to conclude in about 90 days
👀 What to Watch
Track the execution of the Business Transfer Agreement and closing over the next 90 days, along with any margin impact from divesting the Rs 100.56 crore revenue lending unit.
BLSE Arm ATPL to Sell JLG Lending Business with Rs 100.56 Cr FY26 Turnover for Rs 59.49 Lakh
BLS E-Services' wholly owned subsidiary, Atyati Technologies Private Limited (ATPL), has approved a slump sale of its Joint Liability Group (JLG) financial lending business to TVAM Technologies. The business unit recorded a turnover of Rs 100.56 crore in FY26, contributing 26.8% of ATPL's total turnover (and roughly 9.0% of BLSE's TTM consolidated revenue of Rs 1,118 crore). However, the sale consideration is just Rs 59.49 lakh, matching the unit's net worth of Rs 59.49 lakh (0.9% of ATPL net worth). Crucially, the transaction is a related party transaction as a director of ATPL is also a director and shareholder in TVAM.
Confidence: HIGH
What changedATPL approved entering into a BTA to transfer its JLG lending division as a going concern to related party TVAM Technologies for Rs 59.49 lakh.
Why it mattersThe unit represents over a quarter of ATPL's turnover and ~9% of BLSE consolidated revenue; selling it for book value/net worth warrants scrutiny on whether it was loss-making and on corporate governance grounds given the related-party buyer.
FY26 Turnover of unit: Rs. 100.56 CroresTurnover share of ATPL: 26.8%Unit turnover vs BLSE TTM Revenue: ~9.0%Sale consideration: Rs. 59,49,000/-Expected completion timeline: about 90 days
📅 Short termInvestors are likely to evaluate the corporate governance implications of carving out a Rs 100+ crore revenue business to a related entity at Rs 59.49 lakh.
📈 Long termPart of operational restructuring to de-risk or streamline direct lending exposure, though it will shrink top-line growth at the subsidiary level.
⚠ Risk flags
- Related-party transaction involving common directorship between ATPL and TVAM Technologies
- Significant top-line divestment (Rs 100.56 crore revenue) at a nominal consideration of Rs 59.49 lakh
- Subject to approvals from lenders and statutory authorities
Key Highlights
Slump sale of ATPL's JLG lending undertaking to Tvam Technologies for Rs 59,49,000
Divested unit generated Rs 100.56 crore turnover in FY26 (26.8% of ATPL turnover, ~9% of BLSE consolidated TTM revenue)
Net worth of the unit was Rs 59.49 lakh as on July 1, 2026, representing 0.9% of ATPL's net worth
Classified as a related party transaction because an ATPL director is a director and member in TVAM
Transaction expected to be consummated in approximately 90 days subject to lender and regulatory consents
👀 What to Watch
Track the execution of the Business Transfer Agreement (BTA) within the 90-day window and watch for disclosures regarding post-closing adjustments and profitability impact on consolidated numbers.
Prasol Chemicals Reports Q1 FY27 Revenue Up 36% to ₹433.6 Cr; Plans ₹300 Cr Capex
Prasol Chemicals filed its Q1 FY27 earnings presentation following its recent IPO listing on September 16, 2026. Total revenue grew 35.5% YoY to ₹433.6 crore, while EBITDA surged 122.4% YoY to ₹90.3 crore, and PAT increased 150.7% to ₹61.0 crore. Operating margins were temporarily boosted by higher average selling prices worth ₹25 crore due to geopolitical supply chain disruptions. The company plans a ₹300 crore capex for expanding existing product lines and guides for FY27 revenue of ₹1,550–1,650 crore.
Confidence: HIGH
What changedPrasol Chemicals released its first quarterly presentation post-listing, disclosing strong Q1 FY27 performance and formal FY27 operational guidance.
Why it mattersDemonstrates robust top-line growth and turnaround at the Mahad facility, though reported margins benefited from temporary supply-chain-driven price surges.
Q1 FY27 Revenue: ₹433.6 croresQ1 FY27 EBITDA: ₹90.3 croresQ1 FY27 PAT: ₹61.0 croresPlanned Capex: ₹300 croresFY27 Revenue Guidance: ₹1,550–1,650 crores
📅 Short termMarket sentiment should react positively to the strong triple-digit earnings growth, though the management's commentary notes margins will likely normalize in future quarters.
📈 Long termSupported by the turnaround of the Mahad unit, ramp-up in secondary/tertiary derivatives, and ₹300 crore capex into complex specialty chemistries.
⚠ Risk flags
- Margin volatility: Q1 gross profit included a temporary ₹25 crore gain from geopolitical supply-chain disruptions that may not recur.
- Export logistics risk due to ongoing West Asia conflict affecting shipment schedules.
Key Highlights
Q1 FY27 revenue grew 35.5% YoY to ₹433.6 crore versus ₹319.6 crore in Q1 FY26
EBITDA surged 122.4% YoY to ₹90.3 crore, with margins expanding to 20.8% (aided by a ₹25 crore ASP increase)
PAT jumped 150.7% YoY to ₹61.0 crore, with EPS rising to ₹10.52 from ₹4.20
Management provided FY27 guidance of ₹1,550–1,650 crore in revenue and ₹240–250 crore in EBITDA (excluding geopolitical fluctuations)
Planned capex of ₹300 crore in existing product lines alongside turnaround of the Mahad facility
👀 What to Watch
Track the sustainability of EBITDA margins as management expects the ₹25 crore geopolitical pricing tailwind to normalize in upcoming quarters, alongside execution updates on the ₹300 crore capex.
SETL Takes Board Control of GScale Energy; Consolidates as Subsidiary in ₹190 Cr Deal
Standard Engineering Technology Limited (SETL) has obtained control over the board of GScale Energy Private Limited, turning it into a subsidiary effective September 28, 2026. SETL currently holds 50,495 equity shares (a 33.55% stake) and plans to scale up to 51% via cash consideration and a share swap, with total acquisition cost of approximately ₹190 crore. GScale, incorporated recently on May 15, 2026, provides integrated engineering platforms for AI datacenter infrastructure and currently has 1GW+ under execution.
Confidence: HIGH
What changedSETL has appointed representative directors to GScale Energy's board, gaining board control and making it a formal subsidiary despite the shareholding remaining at 33.55%.
Why it mattersGives SETL direct operational entry into the AI datacenter infrastructure sector, diversifying away from its core pharma/chemical equipment operations.
Acquisition cost: Approximately of Rs. 190 CroresAcquisition cost vs TTM revenue: ~0.82%Current shareholding: 33.55%Proposed shareholding: up to 51%Target track record under execution: 1GW+
📅 Short termInvestors will monitor the consolidation of GScale's balance sheet and operational milestones into SETL's quarterly reporting.
📈 Long termCreates a two-platform engineering model expanding SETL into the fast-growing global AI datacenter infrastructure sector.
⚠ Risk flags
- Execution risk in integrating a newly incorporated entity (incorporated May 15, 2026)
- Regulatory approvals pending for expanding equity stake up to 51%
Key Highlights
GScale Energy became a subsidiary of SETL effective September 28, 2026 via board control
Current equity holding is 33.55% (50,495 shares), with approval to acquire up to 51%
Total acquisition cost is approximately ₹190 crore via cash consideration and share swap
Target operates in AI datacenter infrastructure with 486 MW delivered and 1GW+ under execution
👀 What to Watch
Track the completion and regulatory approvals for the remaining stake increase to 51%, as well as financial consolidation in subsequent quarterly results.
Equitas SFB GST Demand Proposed Assessment Slashed 95% to ₹23.95 Cr from ₹533.81 Cr
Equitas Small Finance Bank received a revised communication from the Tamil Nadu GST authorities significantly reducing a proposed assessment. Following a personal hearing on September 25, 2026, the aggregate proposed demand for FY 2022-23 was reduced from ₹533.81 Cr to ₹23.95 Cr. The revised amount comprises ₹21.67 Cr tax, ₹0.11 Cr interest, and ₹2.17 Cr penalty. The bank stated that the reduction followed submissions on loan interest exemptions, and it is submitting further documentation to contest the remaining ₹23.95 Cr demand.
Confidence: HIGH
What changedGST authorities revised the proposed demand from ₹533.81 Cr down to ₹23.95 Cr after reviewing the bank's submissions regarding loan interest exemptions.
Why it mattersThe original demand of ₹533.81 Cr represented over 100% of TTM PAT (₹511 Cr), posing a material overhang; reducing it to ₹23.95 Cr (~4.7% of TTM PAT) substantially eliminates that risk.
Original proposed demand: Rs.533,81,24,251/-Revised proposed demand: Rs.23,95,12,141/-Revised demand vs TTM PAT: ~4.7%Assessment financial year: FY 2022-23
📅 Short termRemoves a major litigation overhang that posed significant downside risk relative to annual net profits.
📈 Long termLimited structural impact, as core operations and asset growth strategy remain unaffected.
⚠ Risk flags
- Remaining ₹23.95 Cr remains subject to verification of supporting documents and final adjudication.
Key Highlights
Proposed GST assessment slashed by ~95.5% from ₹533.81 Cr to ₹23.95 Cr
Revised demand consists of ₹21,67,28,670 tax, ₹11,10,604 interest, and ₹2,16,72,867 penalty
Original notice under Section 73 pertained to FY 2022-23 issued by Central-III Zone, Tamil Nadu
Reduction driven by bank's submissions demonstrating tax exemption on interest income from loans and advances
👀 What to Watch
Track subsequent updates on the final assessment order as the bank submits further documentation to seek full exemption for the remaining ₹23.95 Cr.
Prasol Chemicals Q1 PAT Surges 151% YoY to ₹61.02 Cr; Revenue Up 35.7% to ₹433.65 Cr
Prasol Chemicals reported its first financial results post-listing for the quarter ended June 30, 2026, posting a 150.7% YoY increase in Net Profit to ₹610.23 million (₹61.02 crore) compared to ₹243.38 million in Q1 FY25. Revenue from operations increased 35.7% YoY to ₹4,336.46 million (₹433.65 crore) from ₹3,195.60 million. Profit Before Tax climbed 154.9% YoY to ₹835.58 million. The board also noted the retirement of Dr. Chitra Vaidya, Vice-President – R&D, effective September 30, 2026.
Confidence: HIGH
What changedPrasol Chemicals approved its first post-listing quarterly results (Q1 FY27) and recorded the retirement of its R&D head.
Why it mattersDemonstrates robust top-line growth (35.7% YoY) and significant margin expansion post-IPO, setting the baseline for performance as a newly listed public company.
Revenue from operations (Q1): Rs 4,336.46 millionProfit after tax (Q1): Rs 610.23 millionEPS (Basic and Diluted): Rs 10.52IPO total issue size: Rs 5,000 Million
📅 Short termMarket sentiment should react favorably to the strong YoY jump in quarterly PAT and revenue in its debut post-IPO quarterly reporting.
📈 Long termSustaining quarterly margins above recent annual averages will be key to long-term valuation in the specialty chemicals sector.
⚠ Risk flags
- Retirement of senior R&D management personnel
- Results for Q4 FY26 (ended March 31, 2026) were neither audited nor subject to limited review
Key Highlights
Revenue from operations grew 35.7% YoY to ₹4,336.46 million in Q1 FY27
Net profit after tax rose 150.7% YoY to ₹610.23 million from ₹243.38 million
Diluted EPS increased to ₹10.52 for the quarter compared to ₹4.20 in Q1 FY25
Retirement of Dr. Chitra Vaidya, Vice-President – R&D, effective close of September 30, 2026
Completed ₹5,000 million IPO and listed on NSE/BSE on September 16, 2026
👀 What to Watch
Track the deployment of ₹800 million fresh IPO proceeds and watch how operating margins perform across upcoming quarters following strong Q1 profitability.
Swaraj Suiting Board Approves ₹174.2 Cr Preferential Issue of Shares and Warrants at ₹335/share
The Board of Swaraj Suiting approved raising up to ₹174.20 Cr via preferential allotments to non-promoter investors. This includes up to 35,00,000 equity shares aggregating ₹117.25 Cr and 17,00,000 convertible warrants aggregating ₹56.95 Cr, both at an issue price of ₹335 per instrument. Total fundraise represents roughly 19.7% of the company's current market capitalization of ₹885 Cr. Post-dilution across shares and warrants, promoter holding will decline from 65.06% to 55.87%.
Confidence: HIGH
What changedThe Board approved raising up to ₹174.20 Cr via 35 lakh equity shares and 17 lakh convertible warrants on a preferential basis at ₹335 each.
Why it mattersThe capital injection is significant (~19.7% of market cap and ~51.7% of net worth), which can materially deleverage the balance sheet (debt of ₹327 Cr) or fund ongoing expansions.
Total fundraise value: ₹174.20 CrIssue price per share/warrant: Rs. 335Equity shares to be issued: 35,00,000Warrants to be issued: 17,00,000Fundraise vs Market Cap: ~19.7%Fully diluted promoter stake post-issue: 55.87%
📅 Short termMarket sentiment may react positively to substantial equity infusion from institutional and non-promoter investors at ₹335, close to the market price of ₹355.4.
📈 Long termStrengthens net worth significantly, potentially lowers interest costs if deployed toward debt repayment, and creates balance sheet headroom for future capacity additions.
⚠ Risk flags
- Equity dilution of ~14.1% on fully diluted share base
- Specific end-use of proceeds (capex vs debt reduction vs working capital) not detailed in the filing
- Shareholder and regulatory approvals pending
Key Highlights
Preferential issuance of up to 35,00,000 equity shares at ₹335 per share (₹10 face value + ₹325 premium) raising ₹117.25 Cr
Issuance of up to 17,00,000 convertible warrants at ₹335 each, raising up to ₹56.95 Cr
Total capital raise aggregates up to ₹174.20 Cr across 3 equity institutional investors and 81 warrant subscribers (including employees)
Fully diluted promoter holding to decrease from 65.06% to 55.87%
Extraordinary General Meeting (EGM) scheduled for October 24, 2026 to seek shareholder approval
👀 What to Watch
Track shareholder approval at the EGM on October 24, 2026, and watch for management disclosures regarding the specific end-use of proceeds (debt reduction versus capex).
Edelweiss Announces Early Closure of ₹300 Cr NCD Public Issue on Strong Demand
Edelweiss Financial Services has decided to close its public issuance of Secured Redeemable NCDs early on September 29, 2026, ahead of the original scheduled closing date of October 5, 2026. The issue comprises a base issue size of ₹150 Cr (₹1,500 million) with a greenshoe option of ₹150 Cr, aggregating up to ₹300 Cr (₹3,000 million). The total potential fundraise represents ~2.0% of the company's market cap (₹14,824 Cr) and ~7.5% of total debt (₹3,985 Cr). Early closure indicates healthy investor subscription across retail and institutional tranches.
Confidence: HIGH
What changedThe NCD issue is closing early on September 29, 2026, instead of October 5, 2026, per the Debenture Fund Raising Committee resolution passed on September 28, 2026.
Why it mattersDemonstrates successful access to debt capital markets for retail/secured borrowing, supporting the company's ongoing liquidity and working capital needs.
Base Issue Size: ₹ 1,500 millionIssue Limit (Max): ₹ 3,000 millionIssue Limit vs Debt: ~7.5%Issue Limit vs Market Cap: ~2.0%Revised Closure Date: September 29, 2026
📅 Short termReflects steady retail/debt demand for Edelweiss paper; operational focus will move to allotment and listing of the debentures.
📈 Long termLimited; standard debt market refinancing and liquidity mobilization within the company's regular funding framework.
⚠ Risk flags
- Increases leverage if proceeds are deployed into growth rather than replacing higher-cost borrowings.
Key Highlights
Base issue size of ₹1,500 million (₹150 Cr) with an oversubscription option of up to ₹1,500 million, aggregating to ₹3,000 million (₹300 Cr)
Issue comprises up to 30,00,000 Secured Redeemable NCDs of face value ₹1,000 each
Early closure approved for September 29, 2026, advancing the original close date of October 5, 2026
Total issue limit of ₹300 Cr accounts for ~7.5% of total reported debt of ₹3,985 Cr
👀 What to Watch
Track the final subscription figures and basis of allotment disclosures post-closure to gauge final retail and HNI participation levels.
Control shifts to Anupam Rasayan PAC as outgoing promoters' 34.82% stake reclassified to public
Bliss GVS Pharma has announced the formal completion of its acquisition by Anupam Rasayan India Limited and its affiliate PAC (Mates Visa Consultancy). Following the consummation of the share purchase agreement and open offer, the erstwhile promoter group's holding dropped from 34.82% (3,71,30,124 shares) to 0.01% (8,100 shares). The board noted the formal reclassification of these 27 outgoing promoters to the 'public' category pursuant to SEBI Listing Regulations.
Confidence: HIGH
What changedControl of Bliss GVS Pharma has formally transferred to Anupam Rasayan/PAC, and outgoing promoters holding 34.82% have been reclassified to public shareholders.
Why it mattersA complete change of promoter and control can lead to strategic shifts in capital allocation, therapeutic focus, and management execution for the ₹8,147 Cr company.
Shares transferred by outgoing promoters: 3,71,22,024 sharesOutgoing promoter holding prior: 34.82%Outgoing promoter holding post: 0.01%Narsimha Shibroor Kamath prior stake sold: 30.51%
📅 Short termMarket will watch for reconstituted board members and incoming leadership announcements following the completion of the takeover.
📈 Long termNew ownership under Anupam Rasayan could accelerate expansion into regulated global pharma markets and influence future earnings trajectories.
⚠ Risk flags
- Management transition risks
- Strategic misalignment during post-acquisition integration
Key Highlights
Erstwhile promoter group holding reduced from 3,71,30,124 equity shares (34.82%) to 8,100 shares (0.01%)
Transaction consummated following Share Purchase Agreement dated May 23, 2026, and deed of adherence dated July 17, 2026
Control transfers to Anupam Rasayan India Limited / PAC (Mates Visa Consultancy Private Limited)
27 promoter group members reclassified from 'promoter/promoter group' to 'public' category
👀 What to Watch
Track subsequent disclosures on incoming management appointments, board reconstitution, and any operational synergies outlined by Anupam Rasayan.
Anupam Rasayan and PAC Acquire 47.95% Stake in Bliss GVS, Taking Control as Promoters
Anupam Rasayan India Limited along with PAC (Mates Visa Consultancy) has completed the acquisition of a 47.95% stake (5,09,86,264 shares) in Bliss GVS Pharma Limited, successfully taking control as the new Promoters effective September 28, 2026. Concurrently, Managing Director Mr. Narsimha Shibroor Kamath has resigned from the board. Three new Non-Executive Non-Independent Directors (Hetul Mehta, Amar Shah, and Pramod Kasat) have been appointed, subject to postal ballot approval. This completes the transaction under the Share Purchase Agreement dated May 23, 2026.
Confidence: HIGH
What changedControl of Bliss GVS Pharma has formally transferred to Anupam Rasayan India Limited and PAC with a 47.95% stake, accompanied by the resignation of the incumbent Managing Director.
Why it mattersA complete change in promoters and leadership brings strategic redirection, potential operational synergies with Anupam Rasayan, and changes to capital deployment.
Total shares acquired: 5,09,86,264Acquired equity stake: 47.95%Shares acquired under open offer: 1669Effective date of control change: September 28, 2026
📅 Short termMarket sentiment will reflect the official transition of ownership and the integration with Anupam Rasayan's governance framework.
📈 Long termStructural transformation likely as the new promoter steers the company into newer therapeutic categories or expanded geographic markets beyond semi-regulated African regions.
⚠ Risk flags
- Management transition disruption following the exit of the long-standing Managing Director
- Integration risks between specialty chemical and pharmaceutical formulation operating models
Key Highlights
Acquisition of 5,09,84,595 shares via SPA and 1,669 shares via open offer, totaling 5,09,86,264 shares (47.95% equity stake)
Anupam Rasayan India Ltd and PAC officially classified as new Promoters effective September 28, 2026
Managing Director Narsimha Shibroor Kamath resigned from his role and board positions on September 28, 2026
Three new Non-Executive Non-Independent Directors appointed to the board, subject to shareholder postal ballot approval
👀 What to Watch
Track the outcome of the upcoming postal ballot for board appointments and watch for strategic updates from the new promoters regarding synergies, governance, and capital allocation.
Anupam Rasayan and PAC Acquire 47.95% Stake in Bliss GVS; Complete Management Takeover
Bliss GVS Pharma has announced the formal completion of the transaction under the Share Purchase Agreement dated May 23, 2026. Anupam Rasayan India Limited along with PAC (Mates Visa Consultancy Pvt Ltd) acquired 5,09,86,264 equity shares representing a 47.95% stake in the company, taking over as promoters. Consequent to the change in control, Managing Director Narsimha Shibroor Kamath has resigned effective September 28, 2026. The company appointed three new Non-Executive Non-Independent Directors to the Board, subject to shareholder approval via postal ballot.
Confidence: HIGH
What changedFormal change in control and promoter status to Anupam Rasayan India Ltd and its PAC, accompanied by the resignation of the existing Managing Director and reconstitution of the Board.
Why it mattersA strategic shift in ownership to a prominent chemical/pharma company could unlock operational synergies and new growth initiatives for Bliss GVS Pharma (TTM revenue ₹1,005 Cr).
Shares acquired by PAC & Purchaser: 5,09,86,264Total equity stake acquired: 47.95%Shares acquired in Open Offer: 1,669Market Cap context: ₹8,147 Cr
📅 Short termThe market is likely to react to the finalized management transition and the official onboarding of new board members.
📈 Long termAnupam Rasayan's promoter ownership may aid Bliss GVS Pharma's strategy to expand beyond semi-regulated African markets into higher-margin regulated global pharmaceutical markets.
⚠ Risk flags
- Transition risk associated with executive leadership following the resignation of the long-standing Managing Director
- Integration and strategic alignment risks between Bliss GVS and the new promoter group
Key Highlights
Purchaser and PAC acquired an aggregate 5,09,86,264 shares, representing 47.95% of equity share capital
Open Offer resulted in the acquisition of 1,669 equity shares by the Purchaser
Managing Director Narsimha Shibroor Kamath resigned from the board effective September 28, 2026
Three new Non-Executive Non-Independent Directors (Hetul K. Mehta, Amar D. Shah, Pramod B. Kasat) appointed effective September 28, 2026
👀 What to Watch
Track the outcome of the postal ballot for director appointments and monitor strategic commentary from the incoming management regarding capital allocation, product expansion, and integration synergies.
SAR Televenture acquires 70.17% stake in Tikona Communication to take promoter control
SAR Televenture Limited has completed the acquisition of 2,13,52,650 equity shares, representing a 70.17% stake, in Tikona Communication Limited (formerly Grand Foundry Limited). The acquisition was concluded pursuant to a Share Purchase Agreement dated March 3, 2026, and an Open Offer under SEBI SAST Regulations. Following this transaction, SAR Televenture has acquired complete management control and formally become the promoter of the Target Company. The acquisition expands SAR Televenture's footprint in digital connectivity alongside its existing telecom infrastructure business.
Confidence: HIGH
What changedSAR Televenture closed the acquisition of a controlling 70.17% stake in Tikona Communication Limited and assumed promoter status.
Why it mattersGives the company full operational control over an established communication network asset, expanding its integrated digital connectivity business.
Shares acquired: 2,13,52,650Equity stake acquired: 70.17%SPA agreement date: March 3, 2026Total deal value: not disclosed
📅 Short termPositive sentiment driver as the long-pending acquisition from March 2026 officially reaches closure.
📈 Long termEnhances connectivity offerings and revenue diversification away from geographic reliance on UAE operations if integration succeeds.
⚠ Risk flags
- Integration risks associated with absorbing Tikona Communication's operations
- Total financial outflow/consideration for the transaction not stated in this update
Key Highlights
Acquired 2,13,52,650 equity shares in Tikona Communication Limited
Acquisition represents 70.17% of the paid-up equity share capital of the target
Company becomes the Promoter and gains full control over Tikona Communication
Executed pursuant to SPA dated March 3, 2026 and completed SEBI SAST Open Offer
👀 What to Watch
Track subsequent disclosures on the acquisition consideration and the target company's financial consolidation starting from Q3 FY27.
CARE Upgrades Saksoft's Long-Term Rating to CARE A+; Bank Limit Raised to ₹40 Cr
CARE Ratings Limited has upgraded Saksoft Limited's long-term bank facilities rating to 'CARE A+; Stable' from 'CARE A; Stable'. The rated long-term bank facility limit has been significantly expanded from ₹12.00 crore to ₹40.00 crore. Short-term bank facilities rating was reaffirmed at 'CARE A1' for ₹3.00 crore. This upgrade highlights the company's strong credit profile, supported by minimal debt (₹9 crore) and robust net worth (₹395 crore).
Confidence: HIGH
What changedCARE upgraded Saksoft's long-term credit rating by one notch to CARE A+ and increased rated long-term bank facilities from ₹12.00 crore to ₹40.00 crore.
Why it mattersA credit rating upgrade lowers borrowing costs and enhances credit availability, supporting Saksoft's ongoing acquisition-driven expansion without stretching leverage.
Enhanced Long Term Facility: ₹40.00 crorePrevious Long Term Facility: ₹12.00 croreShort Term Facility: ₹3.00 croreTotal Rated Bank Facilities vs TTM Revenue: ~4.27%
📅 Short termPositive sentiment indicator reflecting the company's solid balance sheet and low debt profile.
📈 Long termEnhances financial flexibility to fund acquisitions and working capital requirements at competitive borrowing rates.
Key Highlights
Long-term bank facilities upgraded to 'CARE A+; Stable' from 'CARE A; Stable'
Long-term facility limits enhanced from ₹12.00 crore to ₹40.00 crore
Short-term bank facilities rating reaffirmed at 'CARE A1' on ₹3.00 crore limits
Total rated bank facilities increased to ₹43.00 crore
👀 What to Watch
Monitor how the expanded credit limit is deployed, particularly towards strategic inorganic acquisitions ('string of pearls' strategy) or working capital needs.
Anupam Rasayan Completes 48.2% Stake Acquisition in Bliss GVS Pharma at ₹299/Share
Anupam Rasayan has concluded the acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share via its subsidiary Mates Visa Consultancy, completing its open offer process. The transaction was funded through a ₹300 crore term loan and ~₹1,450 crore via non-controlling, non-voting instruments led by Bain Capital, Trust Group, and Investec. Bliss GVS adds ₹927 crore in revenue to create a combined pro-forma platform exceeding ₹4,000 crore in revenue and ~₹834 crore in EBITDA. Bliss GVS facilities currently run at ~30% capacity utilisation, providing operating leverage for forward integration into finished dosage formulations.
Confidence: HIGH
What changedAnupam Rasayan finalized payment and completed the acquisition of a 48.2% controlling stake in formulations maker Bliss GVS Pharma.
Why it mattersExtends Anupam Rasayan forward from specialty chemicals and intermediates into finished formulations, scaling group pro-forma revenue to over ₹4,000 crore (~1.6x of TTM revenue).
Acquisition stake: 48.2%Acquisition price per share: ₹299Debt funded: ₹300 croreInvestor instrument funding: ~₹1,450 croreCombined pro-forma revenue: >₹4,000 croreBliss GVS pro-forma revenue vs TTM revenue: ~36.6%
📅 Short termMarket sentiment should react positively to the formal closing of the transaction and integration into consolidated financials without excessive balance-sheet leverage.
📈 Long termCreates an end-to-end integrated platform spanning fluorination raw materials (Tanfac), US CDMO footprint (Jayhawk), and finished formulations (Bliss GVS) with substantial unutilized formulation capacity.
⚠ Risk flags
- Integration execution risks across cross-border and cross-sector operations
- Low existing capacity utilization (30%) requiring active commercialization
- Servicing of non-controlling financial instruments
Key Highlights
Acquired 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share (~24x LTM earnings)
Funding structured via ₹300 crore term loan and ~₹1,450 crore in non-voting instruments led by Bain Capital
Combined pro-forma platform revenue projected at >₹4,000 crore and EBITDA of ~₹834 crore
Bliss GVS brings ₹927 crore pro-forma revenue and 6 facilities operating at ~30% capacity utilisation
👀 What to Watch
Track the upcoming quarterly consolidated results to monitor the margin impact of Bliss GVS integration and assess ramp-up from its current 30% capacity utilisation.
Agastya Energy Approves Related-Party Property Sale and Appoints Alok Jain as Independent Director
Agastya Energy and Infrastructure announced shareholder approval at its 21st AGM for the appointment of Mr. Alok Jain as Non-Executive Independent Director for a 5-year term ending August 12, 2031. Concurrently, shareholders approved the sale of company property to AAG Capital Holdings Private Limited, an entity where a relative of a director is on the board. The property sale agreement was entered into on September 4, 2026, and is expected to be completed in FY 2026-27. Standalone turnover disclosed as of March 31, 2026, stands at Rs 176 Crore, though specific consideration value for the property sale was omitted as 'As per the Agreement'.
Confidence: MEDIUM
What changedShareholders approved the 5-year appointment of Independent Director Alok Jain and cleared the related-party sale of corporate property.
Why it mattersThe property disposal involves an entity connected to a director's relative, making governance oversight and valuation disclosure critical relative to the company's Rs 176 Crore standalone turnover base.
Standalone Turnover (31.03.2026): Rs. 176 CroreIndependent Director Term: 5 consecutive yearsAgreement Date for Sale: 4th September, 2026Expected Completion: F.Y 2026-27Sale Consideration: As per the Agreement
📅 Short termMarket attention will focus on clarity around the consideration value of the property transaction and potential cash inflow details.
📈 Long termBoard strengthening with an experienced Chartered Accountant improves audit oversight, while asset disposal details will define balance sheet changes.
⚠ Risk flags
- Related-party transaction: Buyer AAG Capital Holdings has a director related to a company director
- Omission of specific monetary consideration received for the property disposal in the disclosure
Key Highlights
Appointment of Mr. Alok Jain as Independent Director for a 5-year term from August 13, 2026 to August 12, 2031
Shareholder approval granted for sale of company property to related party AAG Capital Holdings Private Limited
Agreement for property sale entered on September 4, 2026; execution scheduled within FY 2026-27
Company standalone turnover reported at Rs 176 Crore as on March 31, 2026
👀 What to Watch
Monitor upcoming filings for specific financial disclosures regarding the exact consideration amount, realized gains, and cash proceeds from the related-party property sale.
Agastya Energy Approves Related-Party Property Sale and Appoints Alok Jain as Independent Director
Agastya Energy and Infrastructure announced shareholder approval at its 21st AGM for the appointment of Mr. Alok Jain as Non-Executive Independent Director for a 5-year term ending August 12, 2031. Concurrently, shareholders approved the sale of company property to AAG Capital Holdings Private Limited, an entity where a relative of a director is on the board. The property sale agreement was entered into on September 4, 2026, and is expected to be completed in FY 2026-27. Standalone turnover disclosed as of March 31, 2026, stands at Rs 176 Crore, though specific consideration value for the property sale was omitted as 'As per the Agreement'.
Confidence: MEDIUM
What changedShareholders approved the 5-year appointment of Independent Director Alok Jain and cleared the related-party sale of corporate property.
Why it mattersThe property disposal involves an entity connected to a director's relative, making governance oversight and valuation disclosure critical relative to the company's Rs 176 Crore standalone turnover base.
Standalone Turnover (31.03.2026): Rs. 176 CroreIndependent Director Term: 5 consecutive yearsAgreement Date for Sale: 4th September, 2026Expected Completion: F.Y 2026-27Sale Consideration: As per the Agreement
📅 Short termMarket attention will focus on clarity around the consideration value of the property transaction and potential cash inflow details.
📈 Long termBoard strengthening with an experienced Chartered Accountant improves audit oversight, while asset disposal details will define balance sheet changes.
⚠ Risk flags
- Related-party transaction: Buyer AAG Capital Holdings has a director related to a company director
- Omission of specific monetary consideration received for the property disposal in the disclosure
Key Highlights
Appointment of Mr. Alok Jain as Independent Director for a 5-year term from August 13, 2026 to August 12, 2031
Shareholder approval granted for sale of company property to related party AAG Capital Holdings Private Limited
Agreement for property sale entered on September 4, 2026; execution scheduled within FY 2026-27
Company standalone turnover reported at Rs 176 Crore as on March 31, 2026
👀 What to Watch
Monitor upcoming filings for specific financial disclosures regarding the exact consideration amount, realized gains, and cash proceeds from the related-party property sale.
MOMSBELIEF Q1 FY27 Cons PAT at Rs 27.87 Mn vs Loss YoY; Acquires City Pro Group
Rays of Belief Limited (Moms Belief) reported its Q1 FY27 results, showing consolidated revenue from operations jump 136.4% YoY to INR 253.14 million compared to INR 107.06 million in Q1 FY26. Consolidated profit after tax turned around to INR 27.87 million from a net loss of INR 5.37 million in the year-ago quarter. The company noted that its US subsidiary acquired 100% of City Pro Group Inc. effective September 18, 2026. Standalone revenue grew 27.3% YoY to INR 124.91 million with PAT of INR 14.19 million.
Confidence: HIGH
What changedReported strong Q1 FY27 turnaround earnings post-listing and completed the 100% acquisition of US-based City Pro Group Inc.
Why it mattersDemonstrates rapid expansion in the US therapy services market, which now contributes more than half of consolidated revenues and drove the turnaround from loss to profit.
Consolidated Revenue Q1 FY27: INR 253.14 millionConsolidated PAT Q1 FY27: INR 27.87 millionUSA Segment Revenue Q1 FY27: INR 128.23 millionListing Date: September 8, 2026
📅 Short termPositive sentiment likely driven by the robust swing into profitability and post-quarter acquisition disclosure.
📈 Long termExpansion into the US healthcare and neurodevelopmental therapy market via acquisitions offers high revenue potential, subject to execution and cross-border regulatory integration.
⚠ Risk flags
- Integration risk associated with the 100% acquisition of City Pro Group Inc.
- Prior year Q1 comparative figures were not audited or reviewed by statutory auditors as the firm was unlisted
Key Highlights
Consolidated revenue from operations surged 136.4% YoY to INR 253.14 million from INR 107.06 million
Consolidated PAT turned around to INR 27.87 million versus a loss of INR 5.37 million in Q1 FY26
USA segment generated INR 128.23 million (50.66% of total revenue) compared to INR 8.96 million in Q1 FY26
Wholly owned US subsidiary acquired 100% of City Pro Group Inc. effective September 18, 2026
👀 What to Watch
Track the integration and financial impact of the City Pro Group Inc. acquisition in upcoming quarters, as well as the sustainability of operating margins in the US segment.
Persistent Details EUR ~1.27B Nagarro Acquisition; 50%+1 Threshold Met, EGM in Oct for $450M Raise
Persistent Systems has presented updated details on its agreed acquisition of 100% of European IT firm Nagarro SE at an Enterprise Value of EUR ~1.27 billion (EUR 81/share in cash). The transaction valuation reflects 1.27x CY25A EV/Revenue and 9.19x EV/EBITDA, representing a transformative acquisition relative to Persistent's annual revenue base. The minimum acceptance condition of 50% + 1 share has already been met, with an additional 2-week acceptance window ending on October 6, 2026. To fund the transaction, Persistent has scheduled an EGM in October 2026 to approve an equity raise of up to USD 450 million, with combined equity and borrowings capped at USD 1,250 million.
Confidence: HIGH
What changedPersistent released an updated investor presentation confirming that the 50% + 1 share threshold for its takeover of Nagarro has been met, detailing funding caps and an EGM scheduled for October 2026.
Why it mattersNagarro adds ~EUR 1 billion in scale, diversifying Persistent's revenue beyond North America (which currently accounts for 80.6%) and substantially expanding delivery capabilities in Europe and Automotive/Industrial verticals.
Deal Enterprise Value: EUR ~1.27BOffer Price per Share: EUR 81Target Annual Revenue (CY25): ~EUR 1 billionPlanned Equity Raise Limit: up to USD 450MCombined Equity & Borrowing Cap: USD 1,250MDeal EV vs Persistent Market Cap: ~14-15%
📅 Short termFocus will remain on the completion of the additional acceptance window on October 6, 2026, and the upcoming EGM in October for approving the equity dilution and debt borrowing limits.
📈 Long termIf closed and successfully integrated, this transforms Persistent toward a $2.5B+ annualized revenue player, significantly lowering US client concentration and establishing strong presence across Central Europe.
⚠ Risk flags
- Equity dilution risk from up to USD 450M fundraise
- Balance sheet leverage increase under the USD 1,250M combined debt and equity envelope
- Integration execution risks spanning 18,000+ employees and cross-border regulatory clearances (RBI and 2 pending FDI jurisdictions)
Key Highlights
Enterprise Value of EUR ~1.27B (~INR 12,000+ Cr) based on EUR 81 per share in cash, representing ~140% premium to undisturbed price on June 25, 2026
Acquisition adds ~EUR 1 billion in revenue and 18,003 global employees across 38 countries
Minimum acceptance threshold of 50% + 1 share achieved; additional acceptance period closes on October 6, 2026
Funding planned via equity raise of up to USD 450M and borrowings, with combined limit capped at USD 1,250M to be approved at October 2026 EGM
Closing expected in Q4 CY26 / Q1 CY27, subject to remaining 2 FDI filings (3 of 5 approved) and RBI approval
👀 What to Watch
Track the final tender results after the acceptance period ends on October 6, 2026, shareholder approval at the October EGM for the USD 450 million equity raise, and final regulatory clearances from the RBI and remaining FDI jurisdictions.
Subsidiary Axis Max Life Allots ₹686 Cr Subordinated NCDs
Max Financial Services Limited's material subsidiary, Axis Max Life Insurance Limited, has allotted 68,600 unsecured, subordinated, redeemable Non-Convertible Debentures (NCDs) on a private placement basis. The total amount raised is ₹686.003 crore (including ₹30,000 premium) against an issue size of ₹686 crore face value. The instruments carry a 10-year tenor with a call option exercisable at the end of year 5 and annually thereafter. The capital will strengthen the insurer's solvency margin and support business growth.
Confidence: HIGH
What changedAxis Max Life completed the allotment of ₹686 crore subordinated Tier-2 debt via the NSE electronic bidding platform.
Why it mattersSubordinated debt qualifies as regulatory capital under IRDAI norms, boosting solvency buffers without diluting equity at the subsidiary or parent level.
Issue Face Value: INR 686,00,00,000Total Amount Received: INR 686,00,30,000Number of NCDs: 68,600Tenor: 10 yearsFundraise vs Parent Net Worth: ~10.16%
📅 Short termLimited direct share price reaction expected as this is non-dilutive Tier-2 capital raising by the operational insurance subsidiary.
📈 Long termProvides adequate regulatory capital cushion to sustain the target 15-17% APE growth and distribution expansion without requiring equity infusions from MFSL.
⚠ Risk flags
- Interest servicing is subject to IRDAI solvency constraints and regulatory approvals
Key Highlights
Allotment of 68,600 unsecured subordinated NCDs of face value ₹1,00,000 each
Total capital raised stands at ₹686,00,30,000 including a premium of ₹30,000
Tenor of 10 years with call options starting at the end of 5 years
Debt will be listed on the National Stock Exchange of India Limited (NSE)
👀 What to Watch
Monitor Axis Max Life's upcoming solvency ratio disclosures and capital deployment trajectory in future quarterly updates.
